Xultophy 100/3.6 Dosage

Important Dosage Information

•

XULTOPHY 100/3.6 is a combination of insulin degludec and liraglutide.

•

Administer XULTOPHY 100/3.6 by subcutaneous injection once-daily at the same time each day with or without food.

•

The XULTOPHY 100/3.6 pen delivers doses from 10 to 50 units with each injection. Table 1 presents the units of insulin degludec and the milligrams of liraglutide in each dosage of XULTOPHY 100/3.6.

•

The maximum dosage of XULTOPHY 100/3.6 is 50 units daily (50 units of insulin degludec and 1.8 mg of liraglutide).

Recommended Starting Dosage

In patients naïve to basal insulin or a GLP-1 receptor agonist

•

The recommended starting dosage of XULTOPHY 100/3.6 is 10 units (10 units of insulin degludec and 0.36 mg of liraglutide) injected subcutaneously once-daily (see Table 1).

In patients currently on basal insulin or a GLP-1 receptor agonist

•

Discontinue therapy with basal insulin or GLP-1 receptor agonist prior to initiation of XULTOPHY 100/3.6.

•

The recommended starting dosage of XULTOPHY 100/3.6 is 16 units (16 units of insulin degludec and 0.58 mg of liraglutide) injected subcutaneously once-daily (see Table 1).

Table 1: Units of Insulin Degludec and Milligrams of Liraglutide in Each Dosage of XULTOPHY 100/3.6

*The dose counter on the XULTOPHY 100/3.6 pen displays numbers for the even units and displays lines for the odd units.

Titration of XULTOPHY 100/3.6

•

After starting the recommended starting dosage of XULTOPHY 100/3.6, titrate the dosage upwards or downwards by two units (see Table 2) once weekly or twice weekly (every three to four days), based on the patient’s metabolic needs, blood glucose monitoring results, and glycemic control goal until the desired fasting plasma glucose is achieved.

•

To minimize the risk of hypoglycemia or hyperglycemia, additional titration may be needed with changes in physical activity, meal patterns (i.e., macronutrient content or timing of food intake), or renal or hepatic function; during acute illness; or when used with other medications.

Table 2: Recommended Titration of XULTOPHY 100/3.6 (Once or Twice Weekly)

Recommendations Regarding Missed Doses

•

Instruct patients who miss a dose of XULTOPHY 100/3.6 to resume the once-daily dosage regimen as prescribed with the next scheduled dose. Do not administer an extra dose or increase the dose to make up for the missed dose.

•

If more than three days have elapsed since the last XULTOPHY 100/3.6 dose, reinitiate XULTOPHY 100/3.6 at the recommended starting dose to mitigate any gastrointestinal symptoms associated with reinitiation of treatment.

Important Administration Instructions

•

The XULTOPHY 100/3.6 pen is for single-patient-use only.

•

Train patients on proper use and injection technique before initiating XULTOPHY 100/3.6.

•

Always check the label on the XULTOPHY 100/3.6 pen before administration.

•

Inspect visually for particulate matter and discoloration prior to administration. Only use XULTOPHY 100/3.6 if the solution appears clear and colorless.

•

Inject XULTOPHY 100/3.6 subcutaneously into the thigh, upper arm, or abdomen.

•

Rotate injection sites within the same region from one injection to the next to reduce the risk of lipodystrophy and localized cutaneous amyloidosis. Do not inject into areas of lipodystrophy or localized cutaneous amyloidosis.

•

During changes to a patient’s insulin regimen, increase the frequency of blood glucose monitoring.

•

Use XULTOPHY 100/3.6 with caution in patients with visual impairment who may rely on audible clicks to dial their dose.

•

The XULTOPHY 100/3.6 pen dials in one-unit increments.​

•

Do not administer XULTOPHY 100/3.6 intravenously or in an insulin infusion pump.

•

Do not dilute or mix XULTOPHY 100/3.6 with any other insulin or solutions.

•

Do not split the dose of XULTOPHY 100/3.6.